Jean Ferrieres1, Gaetano Maria De Ferrari2, Michel P Hermans3, Moses Elisaf4, Peter P Toth5, Martin Horack6, Philippe Brudi7, Dominik Lautsch7, Lori D Bash8, Carl A Baxter8, Veronica Ashton8, Baishali Ambegaonkar7, Anselm K Gitt6,9. 1. 1 Department of Cardiology, Toulouse Rangueil University Hospital, Toulouse, France; Department of Epidemiology and INSERM UMR 1027, Toulouse University School of Medicine, Toulouse, France. 2. 2 Department of Molecular Medicine University of Pavia, and Cardiac Intensive Care Unit and Laboratories for Experimental Cardiology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy. 3. 3 Division of Endocrinology & Nutrition, Cliniques Universitaires St-Luc and Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium. 4. 4 Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece. 5. 5 CGH Medical Center, Sterling, Illinois, and Ciccarone Center for the Prevention of heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6. 6 Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany. 7. 7 Merck & Co., Inc., Kenilworth, NJ, USA. 8. 8 MSD Ltd, Hoddesdon, United Kingdom. 9. 9 Klinikum der Stadt Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany.
Abstract
BACKGROUND: Patients with coronary heart disease (CHD) and survivors of acute coronary syndrome (ACS) are at very high risk for adverse cardiovascular events. Lowering low-density lipoprotein cholesterol (LDL-C) can reduce the risk, with effective lipid-lowering therapy (LLT) readily available; however, dyslipidemia remains prevalent throughout Europe. DESIGN: The observational Dyslipidemia International Study II (DYSIS II) aimed to identify unmet treatment needs in adult ACS and CHD patients. Data for the seven participating European countries are presented herein. METHODS: The study was carried out from December 2012 to November 2014. Use of LLT and attainment of European-guideline-recommended LDL-C targets were assessed. For ACS patients, changes in lipid levels and LLT were evaluated 4 months post-hospitalization. RESULTS: Of the 4344 patients enrolled, 2946 were attending a physician visit for the assessment of stable CHD, while 1398 had been hospitalized for an ACS event. In both patient sets, mean LDL-C levels were high (89.5 and 112.5 mg/dl, respectively) and <70 mg/dl target attainment extremely poor. The mean daily statin dosage (normalized to atorvastatin potency) was 27 ± 20 mg for CHD and 22 ± 17 mg for ACS patients. Treatment was intensified slightly for ACS subjects after hospitalization, with the dosage reaching 35 ± 24 mg/day. LDL-C target attainment was higher by the end of the 4-month follow up (30.9% and 41.5% for patients on LLT and without LLT at baseline, respectively; p < 0.05). CONCLUSION: Elevated blood cholesterol levels are highly prevalent across Europe, with low numbers of coronary patients reaching their recommended LDL-C target. While use of LLT is widespread, there is significant scope for intensifying treatment.
BACKGROUND:Patients with coronary heart disease (CHD) and survivors of acute coronary syndrome (ACS) are at very high risk for adverse cardiovascular events. Lowering low-density lipoprotein cholesterol (LDL-C) can reduce the risk, with effective lipid-lowering therapy (LLT) readily available; however, dyslipidemia remains prevalent throughout Europe. DESIGN: The observational Dyslipidemia International Study II (DYSIS II) aimed to identify unmet treatment needs in adult ACS and CHD patients. Data for the seven participating European countries are presented herein. METHODS: The study was carried out from December 2012 to November 2014. Use of LLT and attainment of European-guideline-recommended LDL-C targets were assessed. For ACS patients, changes in lipid levels and LLT were evaluated 4 months post-hospitalization. RESULTS: Of the 4344 patients enrolled, 2946 were attending a physician visit for the assessment of stable CHD, while 1398 had been hospitalized for an ACS event. In both patient sets, mean LDL-C levels were high (89.5 and 112.5 mg/dl, respectively) and <70 mg/dl target attainment extremely poor. The mean daily statin dosage (normalized to atorvastatin potency) was 27 ± 20 mg for CHD and 22 ± 17 mg for ACS patients. Treatment was intensified slightly for ACS subjects after hospitalization, with the dosage reaching 35 ± 24 mg/day. LDL-C target attainment was higher by the end of the 4-month follow up (30.9% and 41.5% for patients on LLT and without LLT at baseline, respectively; p < 0.05). CONCLUSION: Elevated blood cholesterol levels are highly prevalent across Europe, with low numbers of coronary patients reaching their recommended LDL-C target. While use of LLT is widespread, there is significant scope for intensifying treatment.
Authors: Christie M Ballantyne; Ulrich Laufs; Kausik K Ray; Lawrence A Leiter; Harold E Bays; Anne C Goldberg; Erik Sg Stroes; Diane MacDougall; Xin Zhao; Alberico L Catapano Journal: Eur J Prev Cardiol Date: 2019-07-29 Impact factor: 7.804
Authors: Ali Allahyari; Tomas Jernberg; Emil Hagström; Margrét Leosdottir; Pia Lundman; Peter Ueda Journal: Eur Heart J Date: 2020-10-21 Impact factor: 29.983
Authors: Ali Allahyari; Tomas Jernberg; Dominik Lautsch; Pia Lundman; Emil Hagström; Jessica Schubert; Robert Boggs; Stina Salomonsson; Peter Ueda Journal: Eur Heart J Qual Care Clin Outcomes Date: 2021-01-25
Authors: Jean Ferrières; François Roubille; Michel Farnier; Patrick Jourdain; Denis Angoulvant; Franck Boccara; Nicolas Danchin Journal: J Clin Med Date: 2021-12-17 Impact factor: 4.241